Practical Strategy for Treating Chronic Kidney Disease (CKD)-Associated with Hypertension

References

• Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl. 2013;3:1–150.
   Web of Science ®Google Scholar
• Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American college of cardiology/American Heart association task force on clinical Practice Hypertension. J Am Coll Cardiol. 2018;71:e13–e115.
   Web of Science ®Google Scholar
• Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021–3104.30165516
   PubMed Web of Science ®Google Scholar
• Japanese Society of Nephrology. Essential points from evidence-based clinical practice guidelines for chronic kidney disease 2018. Clin Exp Nephrol. 2019;23(1):1–15. doi:10.1007/s10157-018-1648-130506489
   PubMed Web of Science ®Google Scholar
• Yu A, Chertow G, Luyckx V, Marsden P, Skorecki K, Taal M. Brenner and Rector’s the Kidney 11th Edition. Elsevier; 2019:90–91
   Google Scholar
• Cushman WC, Evans GW, Byington RP, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–1585.20228401
   PubMed Web of Science ®Google Scholar
• Sim JJ, Shi J, Kovesdy CP, et al. Impact of achieved blood pressures on mortality risk and end-stage renal disease among a large, diverse hypertension population. J Am Coll Cardiol. 2018;283(6):588–597. doi:10.1016/j.jacc.2014.04.065
   Web of Science ®Google Scholar
• Wright JJT. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease -results from the AASK trial-. JAMA. 2002;288:2421. doi:10.1001/jama.288.19.242112435255
   PubMed Web of Science ®Google Scholar
• Klahr S, Levey AS, Beck GJ, et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med. 1994;330:877–884. doi:10.1056/NEJM1994033133013018114857
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939–946.15766995
   PubMed Web of Science ®Google Scholar
• Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154(8):541–548. doi:10.7326/0003-4819-154-8-201104190-0033521403055
   PubMed Web of Science ®Google Scholar
• Hirayama A, Konta T, Kamei K, et al. Blood pressure, proteinuria, and renal function decline: associations in a large community-based population. Am J Hypertens. 2015;28(9):1150–1156. doi:10.1093/ajh/hpv00325673040
   PubMed Web of Science ®Google Scholar
• Wright JT Jr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–2116.26551272
   PubMed Web of Science ®Google Scholar
• Imai E, Ito S, Haneda M, et al. Effects of blood pressure on renal and cardiovascular outcomes in Asian patients with type 2 diabetes and overt nephropathy: a post hoc analysis (ORIENT-blood pressure). Nephrol Dial Transplant. 2016;31(3):447–454. doi:10.1093/ndt/gfv27226152402
   PubMed Web of Science ®Google Scholar
• Xie X, Liu Y, Perkovic V, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728–741. doi:10.1053/j.ajkd.2015.10.01126597926
   PubMed Web of Science ®Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345(12):861–869. doi:10.1056/NEJMoa01116111565518
   PubMed Web of Science ®Google Scholar
• Nistor I, Bolignano D, Haller MC, et al. Why creating standardized core outcome sets for chronic kidney disease will improve clinical practice. Nephrol Dial Transplant. 2017;32(8):1268–1273. doi:10.1093/ndt/gfv36526497055
   PubMed Web of Science ®Google Scholar
• Casas JP, Chua W, Loukogeorgakis S, et al. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet. 2005;366(9502):2026–2033. doi:10.1016/S0140-6736(05)67814-216338452
   PubMed Web of Science ®Google Scholar
• Obi Y, Kalantar-Zadeh K, Shintani A, et al. Estimated glomerular filtration rate and the risk-benefit profile of intensive blood pressure control amongst nondiabetic patients: a post hoc analysis of a randomized clinical trial. J Intern Med. 2018;283(3):314–327. doi:10.1111/joim.1270129044764
   PubMed Web of Science ®Google Scholar
• Li Y, Liang M, Jiang C, et al. Impact of achieved blood pressure on renal function decline and first stroke in hypertensive patients with chronic kidney disease. Nephrol Dial Transplant. 2018;33(3):409–417. doi:10.1093/ndt/gfx26729036427
   PubMed Web of Science ®Google Scholar
• Hsu T-W, Liu J-S, Hung S-C, et al. Renoprotective effect of renin-angiotensin-aldosterone system blockade in patients with predialysis advanced chronic kidney disease, hypertension, and anemia. JAMA Intern Med. 2014;174(3):347–354. doi:10.1001/jamainternmed.2013.1270024343093
   PubMed Web of Science ®Google Scholar
• Furuichi K, Shimizu M, Okada H, et al. Clinico-pathological features of kidney disease in diabetic cases. Clin Exp Nephrol. 2018;22(5):1046–1051. doi:10.1007/s10157-018-1556-429564666
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi:10.1056/NEJMoa150472026378978
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa151592027299675
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Neal B, Perkovic V, et al. Canagliflozin for primary and secondary prevention of cardiovascular events. Circulation. 2018;137(4):323–334. doi:10.1161/CIRCULATIONAHA.117.03203829133604
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi:10.1056/NEJMoa181238930415602
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi:10.1056/NEJMoa181174430990260
   PubMed Web of Science ®Google Scholar
• Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733–794. doi:10.1152/physrev.00055.200921527736
   PubMed Web of Science ®Google Scholar
• Vallon V, Thomson SC. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition. Diabetologia. 2017;60(2):215–225. doi:10.1007/s00125-016-4157-327878313
   PubMed Web of Science ®Google Scholar
• Masuda T, Watanabe Y, Fukuda K, et al. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat. Am J Physiol Renal Physiol. 2018;315(3):F653–f664. doi:10.1152/ajprenal.00143.201829790389
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597. doi:10.1161/CIRCULATIONAHA.113.00508124334175
   PubMed Web of Science ®Google Scholar
• Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics explain the beneficial cardiorenal outcomes in the EMPA-REG OUTCOME study? A unifying hypothesis. Diabetes Care. 2016;39(7):1115–1122. doi:10.2337/dc16-054227289124
   PubMed Web of Science ®Google Scholar
• Baartscheer A, Schumacher CA, Wüst RCI, et al. Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits. Diabetologia. 2017;60(3):568–573. doi:10.1007/s00125-016-4134-x27752710
   PubMed Web of Science ®Google Scholar
• Kamezaki M, Kusaba T, Komaki K, et al. Comprehensive renoprotective effects of ipragliflozin on early diabetic nephropathy in mice. Sci Rep. 2018;8(1):4029. doi:10.1038/s41598-018-22229-529507299
   PubMed Web of Science ®Google Scholar
• Nespoux J, Vallon V. SGLT2 inhibition and kidney protection. Clin Sci. 2018;132:1329–1339. doi:10.1042/CS2017129829954951
   PubMed Web of Science ®Google Scholar
• Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019;20(3):629. doi:10.3390/ijms20030629
   PubMed Web of Science ®Google Scholar
• Dekkers CCJ, Petrykiv S, Laverman GD, et al. Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers. Diabetes Obes Metab. 2018;20(8):1988–1993. doi:10.1111/dom.1330129573529
   PubMed Web of Science ®Google Scholar
• Menne J, Dumann E, Haller H, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med. 2011;154(12):e1002983. doi:10.1371/journal.pmed.1002983
   Web of Science ®Google Scholar
• Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393(10166):31–39. doi:10.1016/S0140-6736(18)32590-X30424892
   PubMed Web of Science ®Google Scholar